Inflammatory molecules: a target for treatment of systemic autoimmune diseases.

[1]  B. Haribabu,et al.  Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. , 2007, Blood.

[2]  Alberto Mantovani,et al.  Tuning inflammation and immunity by chemokine sequestration: decoys and more , 2006, Nature Reviews Immunology.

[3]  V. Pascual,et al.  Type I interferon in systemic lupus erythematosus and other autoimmune diseases. , 2006, Immunity.

[4]  J. Schwab,et al.  Lipoxins and new lipid mediators in the resolution of inflammation. , 2006, Current opinion in pharmacology.

[5]  G. Schmid-Schönbein,et al.  Analysis of inflammation. , 2006, Annual review of biomedical engineering.

[6]  D. Isenberg,et al.  Systemic lupus erythematosus—2005 annus mirabilis? , 2006, Nature Clinical Practice Rheumatology.

[7]  Wen‐chao Song,et al.  Complement regulatory proteins and autoimmunity , 2006, Autoimmunity.

[8]  A. Mantovani,et al.  Migration of dendritic cells across blood and lymphatic endothelial barriers , 2005, Thrombosis and Haemostasis.

[9]  R. Eisenberg,et al.  B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus , 2006, Nature Clinical Practice Rheumatology.

[10]  S. Sozzani.  Dendritic cell trafficking: more than just chemokines. , 2005, Cytokine & growth factor reviews.

[11]  G. Hughes,et al.  Theory, targets and therapy in systemic lupus erythematosus , 2005, Lupus.

[12]  J. Merrill.  BLyS antagonists and peptide tolerance induction , 2005, Lupus.

[13]  A. Mantovani,et al.  Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin , 2005, The Journal of experimental medicine.

[14]  M. Feldmann,et al.  Anti-TNF therapy: where have we got to in 2005? , 2005, Journal of autoimmunity.

[15]  C. Mojcik,et al.  Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus , 2004, Lupus.

[16]  U. V. von Andrian,et al.  Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. , 2004, Annual review of immunology.

[17]  Marc Parmentier,et al.  Specific Recruitment of Antigen-presenting Cells by Chemerin, a Novel Processed Ligand from Human Inflammatory Fluids , 2003, The Journal of experimental medicine.

[18]  C. Lau,et al.  Pathogenesis of systemic lupus erythematosus , 2003, Journal of clinical pathology.

[19]  G. Illei,et al.  A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. , 2003, Arthritis and rheumatism.

[20]  R. Bagin,et al.  LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. , 2003, Arthritis and rheumatism.

[21]  K. Kalunian,et al.  Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[22]  M Locati,et al.  Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. , 2001, Trends in immunology.

[23]  D. Wofsy,et al.  Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide1 , 2001, The Journal of Immunology.

[24]  D. Alarcón-Segovia,et al.  Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. , 2000, Arthritis and rheumatism.

[25]  P. Allavena,et al.  Shaping and tuning of the chemokine system by regulation of receptor expression and signaling: dendritic cells as a paradigm , 2000, Journal of Neuroimmunology.

[26]  M. Feldmann,et al.  The rationale for the current boom in anti-TNFα treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFα and minimise hazards? , 1999, Annals of the rheumatic diseases.

[27]  J. Woody,et al.  Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. , 1997, Advances in immunology.

[28]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[29]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[30]  A. Mantovani,et al.  Rapid induction of arachidonic acid release by monocyte chemotactic protein-1 and related chemokines. Role of Ca2+ influx, synergism with platelet-activating factor and significance for chemotaxis. , 1994, The Journal of biological chemistry.

[31]  J. Ghrayeb,et al.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. , 1993, Arthritis and rheumatism.

[32]  M. Feldmann,et al.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.